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Background/aim: This study evaluates diabetic macular-edema (DME) patients for the effect of intravitreal bevacizumab (IVB)
injection on macular thickness and proangiogenic biomarkers in serum and vitreous.
Materials and methods: Forty DME patients were analyzed for macular thickness (MT). Twelve proangiogenic biomarkers in serum
and vitreous were analyzed before and after IVB.
Results: Significant decrease in MT with vitreal vascular endothelial growth factor-A (VEGF-A) was observed as expected after IVB,
while serum VEGF-A did not follow a decreasing trend in contrast to VEGF-C, which decreased both in serum and vitreous. Other
vitreal factors like bone morphogenetic protein-9 (BMP9) and fibroblast growth factor (FGF) were also significantly decreased, while
endothelial growth factor (EGF) increased following IVB. Before IVB, significant negative correlations were vitreous BMP9 with serum
FGF, vitreous human growth factor (HGF) and interleukin-8 (IL-8) with serum endothelin, and vitreous and serum FGF and serum
placental growth factor (PLGF) with EGF. After IVB, negative correlations in serum vs. vitreous were found for both HGF and PLGF
with BMP9, and angiopoietin with FGF. Cube average thickness was negatively correlated with serum FGF and positively correlated
with vitreous PLGF and endothelin.
Conclusion: Vascular endothelial growth factors are not the only factors that cause macular edema in diabetic patients. The effect of IVB
on different proangiogenic biomarkers indicated a complex interplay of other factors in DME.
Key words: Bevacizumab, central macular thickness, angiogenic factors, vascular endothelial growth factor, placental growth factor

1. Introduction
The National Institute of Health defined a biomarker as “a
characteristic that is objectively measured and evaluated
as an indicator of normal biological processes, pathogenic
processes, or pharmacological responses to a therapeutic
intervention” (1). Later, the World Health Organization in
coordination with the International Labour Organization
and International Program on Chemical Safety defined a
biomarker as “any substance, structure, or process that can
be measured in the body or its products and influence or
predict the incidence of outcome or disease” (2).
Much work is being done to identify proangiogenic
biomarkers in diabetes and in diabetic retinopathy.
Normal vascularization requires a balance between
proangiogenic and antiangiogenic factors. Disturbance
of this balance is seen in many retinal diseases including
diabetic retinopathy. Anti-VEGF drugs are now widely
used for diabetic retinopathy to combat this imbalance.

In the current study, the following angiogenic
biomarkers were analyzed: angiopoietin 2, human growth
factor (HGF), endothelial growth factor (EGF), fibroblast
growth factor (FGF), placental growth factor (PLGF),
vascular endothelial growth factor-A and -C (VEGF-A
and VEGF-C), bone morphogenetic protein 9 (BMP9),
follistatin, leptin, cytokines, interleukin-8 (IL-8), and
angiogenic peptide (endothelin). Moreover, the effect of a
single injection of intravitreal bevacizumab (IVB) on these
factors was also studied in patients with diabetic macular
edema (DME).
BMP9 is a special type of transforming growth factor
(TGF)-β. It plays an important role in the development
of normal vasculature and is seen to be strongly activated
in blood vessels of diabetic patients (3,4). FGF is another
proangiogenic factor, which is raised in serum of patients
with diabetic retinopathy (5). It causes an increase in the
vascular permeability, which results in DME (6). The VEGF
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family is composed of six isoforms: A, B, C, D, E, and PLGF.
Human hepatic growth factor is also a proangiogenic
biomarker and increases vascular permeability. Likewise,
other proangiogenic factors have roles in macular edema.
With the advent of the era of intravitreal injections
of anti-VEGF agents, it is observed that there are certain
patients who do not respond to anti-VEGF therapies.
It has led to the hypothesis that there are some other
angiogenic factors that also play a role in causing macular
edema. There must be a complex interplay of these factors
with interrelated biochemical pathways, which makes
treatment of DME a difficult challenge. This study was
done to identify such proangiogenic factors.
2. Materials and methods
An interventional, time-series study was designed, in
which 40 patients (M = 24, F = 16) with DME were selected
from a tertiary care hospital of Lahore, Pakistan. The
current study was conducted on the basis of Declaration
of Helsinki principles and was approved by institutional
review board of the hospital.
2.1. Study period and design
This was a prospective, interventional time-series study,
conducted from January 2016 to December 2016.
2.2. Exclusion and inclusion criteria
Patients with type 2 diabetes having DME were included in
the study. The exclusion criteria were: patients with type 1
diabetes, patients with any other ocular or systemic disease,
elevated blood pressure, evidence of vitreoretinal interface
abnormality on spectral domain-optical coherence
tomography (SD-OCT), and intravitreal corticosteroids
or anti-VEGF A agents, laser photocoagulation, or
intraocular surgery during the previous 6 months.
2.3. Outcome measures
The primary outcome measure was to find out the values
of serum and vitreous proangiogenic markers and central
macular thickness before and after IVB. The secondary
outcome was to determine correlations among these
biomarkers in vitreous and serum of patients with DME.
2.4. Methods
Clinical history, including ocular as well as systemic
history, was taken. A consent form and the patient’s
proforma were duly filled out prior to examination. Ocular
examination included distance and near visual acuity,
pupillary reactions to light and accommodation, slit-lamp
biomicroscopy, and tonometry. DME was diagnosed with
the help of +78D lens indirect ophthalmoscopy and macular
thickness was measured using SD-OCT (Carl Zeiss, USA,
model 4000). In macular thickness parameters, central
subfield thickness and cube average thickness (CAT)
were taken into account. On the next day of OCT, 5 mL
of blood and 0.1–0.2 mL of vitreous samples were drawn
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by using needle aspiration under strict aseptic conditions
and bevacizumab (1.25 mg/0.05 mL) was injected into
the vitreous cavity. All these procedures were done on the
same day. Vitreous sampling and intravitreal injections
were done using separate needles. Patients were given
topical antibiotics four times a day. OCT was repeated after
4 weeks and blood and vitreous samples were drawn again.
IVB injection was repeated in the patients with residual
macular thickening and the patients who did not require
another injection were excluded from the study. Serum
was separated from all blood samples and all the samples
were stored at –20 °C in properly labeled vials after adding
1X protease inhibitor to reduce the protein degradation.
The patient proforma and consent forms were duly filled
out prior to sampling.
Twelve analytes, angiopoietin 2, leptin, BMP9, IL-8,
HGF, EGF, FGF, PLGF, endothelin, follistatin, VEGF-A,
and VEGF-C, were studied. The xMAP flow cytometry
technique was used to analyze these analytes. The BioPlex multiplex immunoassay system was adopted, which
utilizes xMAP technology licensed from Luminex to
permit the multiplexing of up to 100 different assays
within a single sample. A human angiogenesis/growth
factor magnetic bead panel kit (catalog # HAGP1MAG12K) was used for the current study. Flow cytometry
is the simultaneous measurement of multiple physical
characteristics of a single cell as the cell flows in suspension
through a measuring device. It measures the optical and
fluorescence characteristics of a single cell.
2.5. Statistical analysis
The statistical analysis of all the analytes was conducted
by Mann–Whitney U test. Correlation analyses were done
to estimate predicted associations among different factors,
using Spearman’s rank correlation. All statistical analyses
were performed using SPSS 20.0 (IBM Corp., Armonk,
NY, USA). The significance level was set at P < 0.05.
3. Results
The average age of the patients was 55 years (39–75 years).
There were 60% males and 40% females having 58% right
and 42% left therapeutic eyes. All the study eyes were
phakic. Effects of IVB on macular parameters are shown in
Table 1. Serum endothelin (P = 0.003) and VEGF-C (P =
0.006) were significantly decreased after IVB (Figures 1A
and 1B), while serum PLGF (P = 0.034) and serum FGF
(P = 0.000) were significantly raised after IVB (Figures
1A and 1B). Vitreous BMP9, FGF, VEGF-A, and VEGF-C
were significantly decreased (P = 0.01, 0.04, 0.00, and 0.00,
respectively) and vitreous EGF levels were increased (P =
0.00) after IVB (Figures 2A–2C).
Spearman’s correlation before IVB therapy showed a
negative correlation of vitreous BMP9 with serum FGF (r
= –0.515, P = 0.029), serum PLGF (r = –0.499, P = 0.035)
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Table 1. Macular thickness parameters before and after IVB in the therapeutic eyes.
OCT therapeutic eye

OCT parameters

Before therapy

After therapy

P-value

Central macular subfield thickness (µm)

410.13 ± 24.25

299.55 ± 15.99

<0.01

Macular cube volume (mm )

12.81 ± .36

11.39 ± 0.26

<0.01

Macular cube average thickness (µm)

355.69 ± 10.35

304.69 ± 9.03

<0.01

3

Figure 1. A, B, C) Effects of IVB on different proangiogenic factors. PS = Preinjection serum values, POS = postinjection serum levels.

and serum EGF (r = –0.553, P = 0.017). Serum endothelin
had a negative correlation with vitreous HGF (r = –0.598,
P = 0.009) and vitreous IL-8 (r = –0.515, P = 0.029). Serum
FGF was negatively correlated with vitreous FGF (r =
–0.598, P = 0.009), as shown in Table 2.
After IVB therapy, serum BMP9 was positively
correlated with vitreous endothelin (r = 0.618, P = 0.014).
Serum HGF was negatively correlated with vitreous EGF
(r = –0.802, P = 0.030). Serum PLGF was negatively
correlated with vitreous BMP9 (r = –0.528, P = 0.043).
Serum angiopoietin 2 was negatively related with vitreous
FGF (r = –0.802, P = 0.03) and positively correlated with
VEGF-C (r = 0.762, P = 0.028), as shown in Table 2.

Spearman’s correlation was also calculated between
macular CAT (µm) and 12 proangiogenic factors before
and after IVB therapy. Before IVB therapy, serum leptin was
negatively correlated with cube volume (CV) (r = –0.746)
and CAT (r = –0.0743). However, after IVB therapy, serum
FGF was negatively correlated with CAT (r = –0.540, P
= 0.021). Vitreous PLGF and vitreous endothelin were
positively correlated with CAT (r = –0.546, P = 0.035 and r
= –0.588, P = 0.021, respectively) (Table 2).
4. Discussion
This particular study showed that VEGF-A is not the
only factor affected by IVB; there are other angiogenic
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Figure 2. A, B, C) Effects of IVB on different proangiogenic factors. PV = Preinjection vitreous values, POV = postinjection vitreous levels.
Table 2. Correlations among different proangiogenic factors and cube average thickness.
Name

Factors correlated with (P < 0.05)

Before therapy
Serum Endothelin

Vitreous IL-8 (–0.515) and HGF (0.598**)

Serum FGF

Vitreous FGF (0.598**)

Vitreous BMP9

Serum EGF (–0.553), PLGF (–0.499), and FGF (–0.515)

Serum leptin

CV (–0.746), CAT (–0.0743)

After therapy
Serum BMP9

Vitreous endothelin (0.618)

Serum HGF

Vitreous EGF (–0.802)

Serum PLGF

Vitreous BMP9 (–0.528)

Serum Angiopoietin

Vitreous FGF (–0.802) and VEGF-C (0.762)

CAT

Serum FGF (–0.540), vitreous PLGF (0.546), and endothelin (0.588)
Parentheses contain value of correlation coefficient, ** = highly significant at <0.01 level.

biomarkers that are also significantly affected by IVB.
These factors are separately addressed in the following
discussion.
Vitreous BMP9 was significantly decreased after IVB
(P = 0.01), indicating some common pathway in causing
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DME. We did not find any reference in the literature that
could show the effect of IVB on vitreous BMP9. After IVB,
FGF was significantly reduced in vitreous fluid of DME
patients, but its level was significantly raised in serum. This
paradoxical effect of IVB on serum FGF could be due to
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uncontrolled diabetes, but the vitreous FGF was decreased
due to the local effect of IVB in the vitreous. Although the
literature shows that by injecting intravitreal FGF inhibitor
(dobesilate), there was rapid reduction in macular edema
(7), our study showed that IVB also results in a decrease
in vitreous FGF levels, which in turn influences macular
thickness. Some studies have shown that FGF is involved
in the production of VEGF (8). Thus, its action is direct as
well as indirect through activation of VEGF.
The effect of growth factors on diabetic retinopathy
is not a new concept. Earlier, it was seen that diabetic
retinopathy progression stopped after pituitary ablation.
Similarly, it was also observed that there was an increase
in diabetic retinopathy at the start of puberty, indicating a
role of growth factors in diabetic retinopathy (9–12). We
analyzed VEGF-A and -C in this particular study. Values of
both factors were significantly reduced in the vitreous after
IVB but the effect on serum VEGF-A was not significant.
Prior studies have shown that after IVB serum VEGF-A
was considerably reduced and the effect was also seen on
the other eye, with a significant decrease in macular edema
of the other eye (13).
PLGF has structural similarity with VEGF-A (14).
In prior research, PLGF when injected in rat eyes
induced retinal pigment epithelium (RPE) tight junction
abnormalities and hence retinal edema (15). It acts by
activating vascular endothelial growth factor receptor
(VEGFR-1) (16). This common pathway and structural
similarity with VEGF-A may explain the significantly
decreased levels of PLGF in serum after IVB. However,
vitreous PLGF was raised after IVB. This might be caused
by rebound increase in the vitreous PLGF due to the antiVEGF effect of IVB. Contrary to this, there were some
previous studies that showed that when PLGF was injected
into rat and mouse vitreous, there was no effect on retinal
vessels, suggesting that PLGF had no clear proangiogenic
activity (17). Cao et al. found that VEGF and PLGF affect
pericytes through the ERK signaling pathway mediated
by VEGFR-1, resulting in breakdown of the inner blood
retinal barrier (18,19).
EGF has limited proangiogenic activity when
compared with FGF but they act synergistically (20). This
was supported by our study, where no considerable effect
was seen on serum EGF after injecting IVB.
In this particular study no significant effect of IVB
was seen on the serum and vitreous HGF in patients
with DME, indicating different pathways for its action.
Earlier research showed that vitreous HGF was raised
independently of serum HGF levels (21,22).
Among inflammatory cytokines, IL-8 is produced by
endothelial cells and glial cells of the retina in response
to ischemia (23). Its levels are also increased in diabetic
retinopathy patients as compared to normal controls

(24,25). In another study it was found that IL-8 elevation
occurred as a consequence of VEGF expression (26).
Contrary to that, no significant effect of IVB on serum and
vitreous IL-8 was seen in our study, indicating different
pathways for its activity.
Reduced retinal perfusion is related with upregulation
of endothelin (27). Studies have shown that increased
endothelin was associated with reduced total retinal
blood flow in patients with diabetes (28). Endothelin is
raised in early diabetic retinopathy but it plays no role
in proliferative diabetic retinopathy and DME. It acts as
a vasoconstrictor and results in ischemia of the retina. In
this study, vitreous endothelin was not affected after IVB,
but serum endothelin was significantly reduced.
RPE contains receptors for leptin, which has
proangiogenic activity and is seen in higher concentrations
in the serum of diabetic patients (29–31). No effect of IVB
on vitreous and serum leptin of patients with DME in
our study indicated separate proangiogenic pathways for
leptin in DME.
Follistatin is a protein that is high in the plasma of
diabetic patients (32). However, in this particular study,
no significant effect of IVB was seen on the serum and
vitreous of patients with DME.
Angiopoietin 1 and 2 are natural antagonists of each
other. Angiopoietin 1 has antipermeability activity (33,34).
Their levels depend on the stage of diabetic retinopathy.
Angiopoietin 2 increases the body’s response to VEGF and
results in increased vascular permeability. Angiopoietin 2
in the serum and vitreous of our patients was independent
of IVB.
In this study, the effect of IVB on proangiogenic factors
indicates that there must be certain signaling pathways that
overlap in the mechanism of action of different vascular
endothelial growth factors and inflammatory biomarkers.
A similar correlation study was conducted after
intravitreal implanting of dexamethasone and a complex
relationship was found among three angiogenic factors:
angiopoietin 2, VEGF, and HGF (35). Although new
treatment modalities are directed towards specific VEGF
receptors, further research is needed to target other
proangiogenic factors in DME.
In conclusion, the correlations among different
factors indicated that there exists a complex interplay
of proangiogenic factors and there is a multifactorial
molecular mechanism that controls vascular permeability
of the retina in patients with DME. These factors do not
act independently of each other, making management of
DME a difficult and complicated procedure. This further
explains why there are certain patients who do not
respond to IVB whereas response in other patients is quite
promising. Further research is needed to find out the role
of these agents, which will help in defining new strategies
for treatment of macular edema.
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